相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Endogenous Estrogens Lower Plasma PCSK9 and LDL Cholesterol But Not Lp(a) or Bile Acid Synthesis in Women
Lena Persson et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice
Maxime Denis et al.
CIRCULATION (2012)
Design and Rationale of the LAPLACE-TIMI 57 Trial: A Phase II, Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy
Payal Kohli et al.
CLINICAL CARDIOLOGY (2012)
Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: the JUPITER Trial
Zuhier Awan et al.
CLINICAL CHEMISTRY (2012)
Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification
Kristian Tveten et al.
HUMAN MOLECULAR GENETICS (2012)
Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9
Javier Chaparro-Riggers et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
被撤回的出版物: Plasma PCSK9 Levels and Clinical Outcomes in the TNT (Treating to New Targets) Trial (Retracted article. See vol. 61, pg. 1751, 2013)
Roeland Huijgen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
James M. McKenney et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
Evan A. Stein et al.
LANCET (2012)
PCSK9 LNA Antisense Oligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman Primates
Marie W. Lindholm et al.
MOLECULAR THERAPY (2012)
The biology and therapeutic targeting of the proprotein convertases
Nabil G. Seidah et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
Evan A. Stein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Proprotein Convertase Substilisin/Kexin Type 9 Antagonism Reduces Low-Density Lipoprotein Cholesterol in Statin-Treated Hypercholesterolemic Nonhuman Primates
Hong Liang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor
Oystein L. Holla et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Novel Loss-of-Function PCSK9 Variant Is Associated with Low Plasma LDL Cholesterol in a French-Canadian Family and with Impaired Processing and Secretion in Cell Culture
Janice Mayne et al.
CLINICAL CHEMISTRY (2011)
Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH
Paola Lo Surdo et al.
EMBO REPORTS (2011)
In Vivo Evidence That Furin from Hepatocytes Inactivates PCSK9
Rachid Essalmani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
A Two-step Binding Model of PCSK9 Interaction with the Low Density Lipoprotein Receptor
Taichi Yamamoto et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Novel Domain Interaction Regulates Secretion of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein
Fen Du et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo
Yan G. Ni et al.
JOURNAL OF LIPID RESEARCH (2011)
Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors
Oystein L. Holla et al.
JOURNAL OF LIPID RESEARCH (2011)
PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke
Estelle Rousselet et al.
JOURNAL OF LIPID RESEARCH (2011)
Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure-function relation to therapeutic inhibition
G. Tibolla et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2011)
Circulating Proprotein Convertase Subtilisin Kexin Type 9 Has a Diurnal Rhythm Synchronous With Cholesterol Synthesis and Is Reduced by Fasting in Humans
Lena Persson et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population
Qin Cui et al.
ATHEROSCLEROSIS (2010)
A Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) C-terminal Domain Antibody Antigen-binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein Uptake
Yan G. Ni et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Effects of the Prosegment and pH on the Activity of PCSK9 EVIDENCE FOR ADDITIONAL PROCESSING EVENTS
Suzanne Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
A new method for measurement of total plasma PCSK9: clinical applications
Genevieve Dubuc et al.
JOURNAL OF LIPID RESEARCH (2010)
Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans
Jeffrey D. Browning et al.
JOURNAL OF LIPID RESEARCH (2010)
PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain
Mali Liu et al.
JOURNAL OF LIPID RESEARCH (2010)
Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters
Bin Dong et al.
JOURNAL OF LIPID RESEARCH (2010)
High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol
Greg Welder et al.
JOURNAL OF LIPID RESEARCH (2010)
A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
Nidhi Gupta et al.
PLOS ONE (2010)
Molecular basis of PCSK9 function
Gilles Lambert et al.
ATHEROSCLEROSIS (2009)
Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells
Tommaso Fasano et al.
ATHEROSCLEROSIS (2009)
Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor
Christopher J. Duff et al.
BIOCHEMICAL JOURNAL (2009)
Plasma Proprotein Convertase Subtilisin/Kexin Type 9: A Marker of LDL Apolipoprotein B-100 Catabolism?
Dick C. Chan et al.
CLINICAL CHEMISTRY (2009)
Plasma PCSK9 Is Associated with Age, Sex, and Multiple Metabolic Markers in a Population-Based Sample of Children and Adolescents
Alexis Baass et al.
CLINICAL CHEMISTRY (2009)
Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants
Matthew J. Bottomley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Hepatocyte Nuclear Factor 1α Plays a Critical Role in PCSK9 Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine
Hai Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells
Markey C. McNutt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation EVIDENCE FOR AN INTRACELLULAR ROUTE
Steve Poirier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Genetic and Metabolic Determinants of Plasma PCSK9 Levels
Susan G. Lakoski et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice
Yi Luo et al.
JOURNAL OF LIPID RESEARCH (2009)
PCSK9: a convertase that coordinates LDL catabolism
Jay D. Horton et al.
JOURNAL OF LIPID RESEARCH (2009)
Looking Ahead to the Next 75 Years for The Journal of Pediatrics and Medical Publishing
Glen Campbell et al.
JOURNAL OF PEDIATRICS (2009)
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
Joyce C. Y. Chan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa
Vivienne M. Homer et al.
ATHEROSCLEROSIS (2008)
PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide
LiXin Shan et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment
Gilles Lambert et al.
CLINICAL CHEMISTRY (2008)
Proprotein convertase Subtilisin/Kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
Ahmed Zaid et al.
HEPATOLOGY (2008)
Annexin A2 Is a C-terminal PCSK9-binding Protein That Regulates Endogenous Low Density Lipoprotein Receptor Levels
Gaetan Mayer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Functional analysis of sites within PCSK9 responsible for hypercholesterolemia
Shilpa Pandit et al.
JOURNAL OF LIPID RESEARCH (2008)
Plasma PCSK9 preferentially reduces liver LDL receptors in mice
Aldo Grefhorst et al.
JOURNAL OF LIPID RESEARCH (2008)
Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
Janice Mayne et al.
LIPIDS IN HEALTH AND DISEASE (2008)
Molecular basis for LDL receptor recognition by PCSK9
Hyock Joo Kwon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor
Da-Wei Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
Maria Frank-Kamenetsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2
Hyun Jeong Jeong et al.
JOURNAL OF LIPID RESEARCH (2008)
Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9
Holly E. Careskey et al.
JOURNAL OF LIPID RESEARCH (2008)
Serum proprotein convertase subtilisin Kexin type 9 is correlated directly with serum LDL cholesterol
William E. Alborn et al.
CLINICAL CHEMISTRY (2007)
Plasma PCSK9 levels correlate with cholesterol in men but not in women
Janice Mayne et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity
Jun Li et al.
BIOCHEMICAL JOURNAL (2007)
Versatility in ligand recognition by LDL receptor family proteins: advances and frontiers
Stephen C. Blacklow
CURRENT OPINION IN STRUCTURAL BIOLOGY (2007)
The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
Amanda J. Hooper et al.
ATHEROSCLEROSIS (2007)
Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells
Markey C. McNutt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation
Timothy S. Fisher et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation
Da-Wei Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR
Nasha Nassoury et al.
TRAFFIC (2007)
Unravelling the functional significance of PCSK9
Gilles Lambert
CURRENT OPINION IN LIPIDOLOGY (2007)
The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol
Derek E. Piper et al.
STRUCTURE (2007)
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia
David Cunningham et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2007)
Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
Mark J. Graham et al.
JOURNAL OF LIPID RESEARCH (2007)
Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly
Oystein L. Holla et al.
BMC CELL BIOLOGY (2007)
Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk
S. E. Humphries et al.
JOURNAL OF MEDICAL GENETICS (2006)
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice
Thomas A. Lagace et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A-Functional consequences of natural mutations and post-translational modifications
Suzanne Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: Lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor
Gilles Lambert et al.
ENDOCRINOLOGY (2006)
Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy
KE Berge et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c
P Costet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote
Zhenze Zhao et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene - Long-term follow-up and treatment response
RP Naoumova et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells
F Lalanne et al.
JOURNAL OF LIPID RESEARCH (2005)
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
S Rashid et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment
KN Maxwell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
C Jonathan et al.
NATURE GENETICS (2005)
Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia
TP Leren
CLINICAL GENETICS (2004)
A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree
KM Timms et al.
HUMAN GENETICS (2004)
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia
G Dubuc et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver
SW Park et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
NARC-1/PCSK9 and its natural mutants -: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol
S Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype
KN Maxwell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes
JD Horton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):: Liver regeneration and neuronal differentiation
NG Seidah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice
KN Maxwell et al.
JOURNAL OF LIPID RESEARCH (2003)
分享论文
